ArticleCancers2023

First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors.

Anna R Schreiber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.